Issued: 29 July 2026, London UK
GlaxoSmithKline Capital plc publication of Interim Management Report 2026
GlaxoSmithKline Capital plc (the "Company") today announced the publication on the GSK Group ("GSK") website, www.gsk.com*, of its Interim Management Report in respect of the half year ended 30 June 2026.
In compliance with the UK Financial Conduct Authority's ("FCA") UK Listing Rules sourcebook rule 9.6.1, a copy of the Company's 2026 Interim Management Report has been submitted to the FCA's National Storage Mechanism ("NSM") submission portal via the Electronic Submission System.
The Company is applying the exemption available to it under the FCA's Disclosure Guidance and Transparency Rules sourcebook rule 6.3.5(1A) and has made the regulated information available in unedited full text on the NSM, rather than setting out the full text of the regulated information within this announcement.
A copy of the Company's Interim Management Report in respect of the half year ended 30 June 2026, which includes a description of the principal risks and uncertainties affecting it, together with a Directors' responsibility statement, can be viewed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
V A Whyte
Company Secretary
29 July 2026
* https://www.gsk.com/en-gb/company/codes-standards-and-reports/#gsk-capital-plc-annual-reports
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and GSK's Q2 Results for 2026.
Registered in England & Wales:
No. 02258699
Registered Office:
79 New Oxford Street
London
WC1A 1DG
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DOCRLMITMTJTBMF